Cerebral Amyloid Angiopathy Increases Dementia Risk in Memory Clinics

Vascular Amyloid and the Path to Cognitive Decline

Cerebral amyloid angiopathy, a common form of small vessel disease marked by amyloid-beta deposition in cortical and leptomeningeal artery walls, is increasingly implicated as a driver of vascular cognitive impairment [1, 2]. While known for its association with lobar intracerebral hemorrhage, its role as a frequent comorbidity in Alzheimer disease complicates prognosis [3, 4]. Clinicians often face a diagnostic challenge, as many older adults with vascular lesions on imaging remain asymptomatic for years [5, 6]. However, the presence of markers like white matter hyperintensities has been linked to a nearly twofold increase in dementia risk [7]. A recent longitudinal study from the MEMENTO cohort provides new clarity on the prognostic weight of specific cerebral amyloid angiopathy imaging markers in outpatients presenting with their first cognitive complaints.

Longitudinal Tracking of the MEMENTO Cohort

To investigate this connection, researchers performed a retrospective analysis of the MEMENTO prospective cohort, which enrolled outpatients from 26 memory clinics across France. The study focused on a clinically crucial population: individuals over 50 with subjective cognitive complaints but minimal functional impairment, defined by a Clinical Dementia Rating (CDR) scale score of 0.5 or less. The CDR is a standard tool for staging cognitive severity, where a score of 0.5 signifies very mild impairment not yet meeting the criteria for dementia. Of the 2,323 participants in the MEMENTO cohort, 2,136 (92%) with interpretable baseline brain MRI were included. The study population had a mean age of 71.3 years (SD 7.9), and 1,320 (62%) were women. These participants were monitored with systematic cognitive assessments every six months for five years, yielding a median follow-up of 5.0 years (interquartile range 3.1 to 5.1). This intensive follow-up provided a detailed view of the progression from mild symptoms to a formal dementia diagnosis, the study's primary outcome, which was determined by an expert committee using Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision (DSM-IV) criteria. Over the course of the study, 307 participants progressed to dementia, allowing for a robust analysis of baseline imaging predictors.

Comparing Boston Criteria Versions for Risk Stratification

The study's central analysis involved classifying the 2,136 participants into four groups based on their baseline MRI: probable cerebral amyloid angiopathy (CAA), possible CAA, deep or mixed small vessel disease (SVD), or controls with no SVD imaging markers. This classification was performed using two different versions of the Boston criteria, the standard radiologic guidelines for diagnosing CAA based on the location and type of cerebral microbleeds and other lesions. The use of both the older V1.5 and the updated V2.0 criteria allowed for a direct comparison of their diagnostic and prognostic utility. The choice of criteria substantially impacted the identified prevalence of the condition. Using the broader Boston criteria V2.0, probable CAA was diagnosed in 413 patients (19.3%), while the more restrictive Boston criteria V1.5 identified only 144 patients (7.0%). This difference arises because the V2.0 criteria incorporate non-hemorrhagic markers such as cortical superficial siderosis, which are linear iron deposits on the brain's surface indicative of chronic, subtle micro-hemorrhages. Despite this difference in prevalence, both criteria identified patients at elevated risk. Compared with controls, patients with probable CAA by V2.0 criteria had an increased risk of dementia (hazard ratio 1.73, 95% CI 1.23-2.42). However, the older V1.5 criteria isolated a smaller group with a more pronounced risk; these patients had a hazard ratio for dementia of 2.23 (95% CI 1.56-3.20). These results suggest that while the V2.0 criteria may be more sensitive for detecting CAA in a memory clinic population, the V1.5 criteria appear more specific for identifying individuals at the highest risk of progressing to dementia.

Confounding Factors and the Role of APOE Genotype

To isolate the independent predictive value of CAA, the researchers performed a multivariable analysis, adjusting for established markers of neurodegeneration. After controlling for age, sex, baseline Mini-Mental State Examination score, and hippocampal volume (an MRI marker of atrophy associated with Alzheimer disease), the prognostic significance of the two criteria diverged. The increased dementia risk for patients with probable CAA per the Boston criteria V1.5 remained significant. In contrast, the association for patients meeting the V2.0 criteria was no longer statistically significant after these adjustments. This finding suggests that for the broader population identified by V2.0, the progression to dementia may be driven more by co-existing factors like baseline cognitive status or Alzheimer-related atrophy than by the vascular pathology alone. The analysis was further refined by including the APOE ε4 genotype, a potent genetic risk factor for both Alzheimer disease and CAA. When the APOE ε4 allele was added to the model, the association between probable CAA by V1.5 criteria and dementia risk also lost its statistical significance. This suggests a potential mediation effect, where the APOE ε4 genotype may be a common upstream driver of both the amyloid deposition in blood vessels and the subsequent cognitive decline. For clinicians, these findings underscore that while radiologic markers of CAA are common and confer significant risk in patients with mild cognitive symptoms, this risk is deeply intertwined with a patient's neurodegenerative burden and genetic predisposition.

References

1. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke. 2011. doi:10.1161/str.0b013e3182299496

2. Rannikmäe K, Samarasekera N, Martînez-Gonzâlez NA, Salman RA, Sudlow CLM. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis.. Journal of neurology, neurosurgery, and psychiatry. 2013. doi:10.1136/jnnp-2012-303898

3. Malhotra K, Theodorou A, Katsanos AH, et al. Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis.. Stroke. 2022. doi:10.1161/STROKEAHA.121.035836

4. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016. doi:10.15252/emmm.201606210

5. Avan A, Amiri A, Mokhber N, et al. Association of lewy bodies, hippocampal sclerosis and amyloid angiopathy with dementia in community-dwelling elderly: A systematic review and meta-analysis.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2021. doi:10.1016/j.jocn.2021.05.044

6. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer s & Dementia. 2012. doi:10.1016/j.jalz.2011.10.007

7. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010. doi:10.1136/bmj.c3666